zonisamide

ApprovedWithdrawn

0 views this week 0 watching💤 Quiet

Interest: 35/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

✓

Phase 3

Approved

Indication / Disease

Fibromyalgia

Conditions

Fibromyalgia, Migraine

Trial Timeline

Aug 1, 2004 → Jan 1, 2008

NCT ID

NCT00259636

About zonisamide

zonisamide is a approved stage product being developed by Eisai for Fibromyalgia. The current trial status is withdrawn. This product is registered under clinical trial identifier NCT00259636. Target conditions include Fibromyalgia, Migraine.

What happened to similar drugs?

10 of 20 similar drugs in Fibromyalgia were approved

Approved (10) Terminated (2) Active (10)

✅DuloxetineEli LillyApproved

✅duloxetine hydrochloride + placeboEli LillyApproved

✅Duloxetine + PlaceboEli LillyApproved

✅Eszopiclone + placeboSumitomo PharmaApproved

✅QuetiapineAstraZenecaApproved

✅amitriptyline + quetiapineAstraZenecaApproved

✅PregabalinPfizerApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (6)

NCT ID	Phase	Status	Start	Completion	Indication
NCT01283256	Pre-clinical	Completed	Jan 1, 2011	May 1, 2013	Partial, Generalized and Combined Seizures
NCT01136954	Phase 3	Completed	Jul 1, 2008	Mar 1, 2012	Partial Seizures
NCT00659958	Approved	Completed	Apr 1, 2008	Sep 1, 2009	Epilepsy
NCT01140867	Approved	Completed	Feb 29, 2008	Mar 31, 2011	Epilepsy
NCT00259636	Approved	Withdrawn	Aug 1, 2004	Jan 1, 2008	Fibromyalgia
NCT00056576	Phase 3	Completed	Feb 1, 2002	Oct 1, 2004	Epilepsy, Complex Partial

Competing Products

20 competing products in Fibromyalgia

See all competitors

Product	Company	Stage	Hype Score
DS-5565 + Pregabalin + Placebo tablet + Placebo capsule	Daiichi Sankyo	Phase 3	40
DS-5565	Daiichi Sankyo	Phase 3	40
DS-5565 + Placebo	Daiichi Sankyo	Phase 3	40
DS-5565 + Pregabalin + Placebo tablet + Placebo capsule	Daiichi Sankyo	Phase 3	40
DS-5565 + Pregabalin + Placebo tablet + Placebo capsule	Daiichi Sankyo	Phase 3	40
ASP8062 + Placebo	Astellas Pharma	Phase 2	35
ASP0819 + Placebo	Astellas Pharma	Phase 2	35
Duloxetine	Shionogi	Phase 3	40
Duloxetine 60 mg + Placebo	Shionogi	Phase 3	40
ONO-1110 + Placebo	Ono Pharmaceutical	Phase 2	42
Duloxetine	Eli Lilly	Approved	35
duloxetine hydrochloride + placebo	Eli Lilly	Approved	43
duloxetine	Eli Lilly	Phase 3	40
Duloxetine + placebo	Eli Lilly	Phase 3	40
Duloxetine + Placebo	Eli Lilly	Phase 3	40
Duloxetine + Placebo	Eli Lilly	Approved	43
Treatment for Fibromyalgia	Eli Lilly	Pre-clinical	26
Duloxetine + Placebo	Eli Lilly	Phase 3	40
duloxetine + placebo	Eli Lilly	Phase 3	40
Eszopiclone + placebo	Sumitomo Pharma	Approved	43